Navigation Links
GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
Date:9/17/2013

LONDON, Sept. 18, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.  

Over the last five years, GW has conducted an extensive pre-clinical cannabinoid research program in the field of epilepsy in collaboration with the University of Reading in the United Kingdom. This research has led to the emergence of a number of promising cannabinoid therapeutic candidates showing anti-epileptic effects. GWP42006, one of the most promising of those candidates, is a non-psychoactive cannabinoid extracted from specific chemotypes of the cannabis plant which has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs1.

"We are pleased to have advanced GWP42006 to first dose in man, a significant milestone in the development of this novel product candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," stated Dr. Stephen Wright, Director of Research and Development at GW. "We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Dr. Ben Whalley, Senior Lecturer in Pharmacology at the Reading School of Pharmacy, said, "Our research collaboration with GW over the last several years has shown that GWP42006 not only exerts significant anticonvulsant effects in a wide range of preclinical models of seizure and epilepsy but is also better tolerated compared to existing anti-epileptic drugs. It is also noteworthy that GWP42006 appears to employ a different mechanism of action to currently available anti-epileptic
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Teva Pharmaceuticals Donates to the National Multiple Sclerosis Society in recognition of Jack Osbourne as He Competes on "Dancing with the Stars"
2. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
3. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
4. Frost & Sullivan Lauds Adcock Ingrams Capability to Innovatively Cater to the Dynamic Needs of Emerging Pharmaceuticals Markets
5. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
6. Access Pharmaceuticals Awarded Second European Patent for MuGard
7. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
8. Caldera Pharmaceuticals Announces Closing of Financing
9. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... UPI ), a medical device company that ... voiding dysfunctions, today reported financial results for the fiscal ... revenue for the Company,s Urgent ®  PC Neuromodulation System ... record, as compared to $3.9 million in the third ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
(Date:1/22/2015)... PARK, Calif. , Jan. 22, 2015 Increasing ... the continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research ... chose a single-source solution for their translation and localization ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Connecticut, June 27, 2011 ,   ... Stockholm : SECT B) and Royal Philips Electronics,(AEX: PHI, ... which Philips,will acquire Sectra , s mammography modality,operations. ... on cash and debt-free basis. The agreement,also includes an additional ...
... PARK, Calif., June 27, 2011 Auxogyn, Inc., a ... health, today announced that the U.S. Patent and Trademark ... parameters for the assessment of embryo viability during ... early embryo viability assessment (Eeva™) System. ...
Cached Medicine Technology:Sectra and Philips Sign Large Mammography Modality Acquisition Deal 2Sectra and Philips Sign Large Mammography Modality Acquisition Deal 3Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization 2
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... at the University of California, San Diego School of Medicine ... a study that could help improve therapies to treat cancer. ... a structure that pinches the mother cell into two ... issue of the journal Science . , The division ...
... advantages of fixed-ratio drug delivery and lay the ... first-line and first-relapse Acute Myeloid Leukemia (AML) settings ... N.J., Dec. 9 Celator Pharmaceuticals today announced ... CPX-351 (cytarabine:daunorubicin) Liposome Injection established the recommended dose ...
... Skin graft fixation for burn victims using fibrin sealant ... Company , , MONTREAL, ... specialty bio-therapeutics company developing high-value human plasma-derived protein products ... preclinical study conducted on the use of its proprietary ...
... outsourced IT infrastructure and data center solutions, announced today the opening of ... in Orem, UT. Voonami also announced two new adaptive computing data ... Each new data center will house up to 100,000 square feet with ... ...
... but Australian champion runner Craig Mottram had one more challenge to complete ... ... December 9, 2008 -- The historic inaugural HBA Great Australian Run may ... to complete. , , , , ,Mottram, who was competing over ...
... YORK, Dec. 8 Flu Season is officially here - ... many others it can be deadly.,Here,s the 4-1-1 on protecting ... Listen to this report from UnitedHealthcare at:, http://media.medialink.com/WebNR.aspx?story=36045 ... can access video, audio, text, graphics and photos,for free and ...
Cached Medicine News:Health News:From mother to daughters: A central mystery in cell division solved 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Haemacure's Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury 2Health News:Haemacure's Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury 3Health News:Voonami, Inc. Announces Three New Adaptive Data Centers 2Health News:Mottram Honours His End of the HBA Great Australian Run challenge 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: